While treatment of melanoma patients has been revolutionized with molecularly targeted therapeutics against the most frequently altered signaling cascade in melanoma—the RAS/RAF/MEK/ERK (MAPK) pathway, the majority of patients relapse within months [35,36,37,38]. The gene discussed is MAP2K7; the disease is melanoma.